Arora R, Thakur J S, Azad R K, Mohindroo N K, Sharma D R, Seam R K
Departments of Otorhinolaryngology-Head and Neck Surgery, I G Medical College, Shimla, India.
Indian J Cancer. 2009 Oct-Dec;46(4):311-7. doi: 10.4103/0019-509X.55551.
Cisplatin-induced ototoxicity shows high interindividual variability and is often accompanied by transient or permanent tinnitus. It is not possible to identify the susceptible individuals before commencement of the treatment. We conducted a prospective, randomized and observational study in a tertiary care centre and evaluated the effects of different doses of cisplatin on hearing.
Fifty-seven patients scheduled for cisplatin-based chemotherapy were included in the study. All patients were divided into three groups depending on the dose of cisplatin infused in 3 weeks.
The subjective hearing loss was found in seven patients, while six patients had tinnitus during the chemotherapy. The hearing loss was sensorineural, dose dependent, symmetrical, bilateral and irreversible. Higher frequencies were first to be affected in cisplatin chemotherapy.
As use of high-frequency audiometry is still limited in research work only, we need a strict protocol of adding high-frequency audiometry in the cisplatin-based chemotherapy regimen.
顺铂诱导的耳毒性存在高度个体差异，且常伴有短暂或永久性耳鸣。在治疗开始前无法识别易患个体。我们在一家三级医疗中心进行了一项前瞻性、随机观察性研究，评估了不同剂量顺铂对听力的影响。
本研究纳入了57例计划接受顺铂化疗的患者。根据3周内输注顺铂的剂量，将所有患者分为三组。
化疗期间，7例患者出现主观听力损失，6例患者出现耳鸣。听力损失为感音神经性、剂量依赖性、对称性、双侧性且不可逆。在顺铂化疗中，高频首先受到影响。
由于高频听力测定仅在研究工作中使用受限，我们需要在基于顺铂的化疗方案中加入高频听力测定的严格方案。
